Shares of CalciMedica Inc. (CALC) touched a new 52-week high of $6.40 last week, as investors look ahead to data related to the company's lead drug candidate, Auxora, in the coming months.
This clinical-stage biopharmaceutical company is developing calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The lead drug candidate, Auxora, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.